apceth Received the Second Round of Funding for Its Innovative Stem Cell-Based Cancer Therapeutic as Part of the m4 Initiative of the Munich Biotech Cluster

apceth logo

  • Development of apceth’s first innovative “Advanced Therapy Medicinal Product” based on modified adult stem cells for cancer therapy
  • apceth as participant in the “m4 Personalized Medicine and Targeted Therapies” initiative of the Munich Biotech Cluster
  • A total of 4.7 million € of approved budget in two funding phases

Munich, Germany, February 4, 2013 / B3C newswire / – As of January 2013 apceth has entered the second round of funding for the development of its first cancer therapeutic based on patient’s own modified adult mesenchymal stem cells (MSC) running under the portfolio name Agenmestencel-T.

In December 2012 apceth has successfully concluded the first 2.5-year round of funding through the Federal Ministry of Education and Research (BMBF) for the development of Agenmestencel-T as part of the Munich Biotech Cluster initiative “m4 Personalized Medicine and Targeted Therapies” (Cluster project PM5, FKZ: 16EX1021K).

The Munich Biotech Cluster comprises a rich network of biotech and pharma companies, research institutions and clinical centers in order to promote and expedite the creation of the future orientated personalized and targeted therapy strategies. As the winner of the second round of the “Leading-Edge Cluster Competition” in 2010 the Munich Biotech Cluster has at its disposal a considerable funds granted by BMBF and the Bavarian Government within its “m4 Personalized Medicine and Targeted Therapies” initiative for this ambitious aim.

The second round of funding through BMBF apceth was granted at the end of 2012 as part of the m4 Cluster initiative. With this apceth’s total approved budget for the development of Agenmestencel-T amounted to 4.7 million € within a period of less than five years between July 2010 and March 2015.

Agenmestencel-T is a highly innovative stem cell-based medicinal product for personalized therapy of advanced and/or metastatic cancers. With Agenmestencel-T apceth is committed to provide a novel cell-based cancer drug which will be custom-made for every single patient. Combining the stringent principles of pharmaceutical development with targeted biomarker-based strategies for patient stratification, apceth aims to create the cancer drugs of uppermost quality and safety, while identifying those cancer patients that can mostly benefit from this novel cell therapy.

About apceth
apceth is one of the leading European pioneers in the development, GMP manufacturing and clinical implementation of innovative stem cell-based therapies for the treatment of malignant and non-malignant diseases. apceth combines the principles of stem cell biology with groundbreaking technologies, applying the highest standards for GMP manufacturing, safety regulations and quality control according to the European Regulation for “Advanced Therapy Medicinal Products” (ATMPs). apceth provides novel cell therapy solutions for the treatment of clinical conditions for which no satisfactory treatment options are available to date. The proven know-how in all aspect of ATMP pharmaceutical development and GMP production (GMP manufacturing license, §13 and §20b AMG) enable apceth also to offer the contract manufacturing services for diverse ATMPs.

apceth was founded in 2007 as a start-up company and is privately owned by its founders and private investors.

Dr. Christine Günther, CEO
Prof. Dr. Ralf Huss, CSO

apceth GmbH & Co. KG
Max-Lebsche-Platz 30
D-81377 Munich

Phone: +49 (0)89-7009 608-0
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.